One in five (19%) firms over 200 workers covers GLP-1 agonists for weight loss with more coverage among larger firms One-in-five (19%) firms with 200 or more workers, including 43% of firms with 5,000 or more workers, cover GLP-1 drugs for weight loss in their largest health plan in 2025
Severe adverse effects (requiring study discontinuation) were reported in 6.7% of cases and 3.0% of controls
Anxiety Reduction: Calming the Mind Anxiety and obesity frequently coexist, creating a feedback loop where worry drives overeating and weight gain intensifies worry
Many patients notice reduced hunger, improved portion control, and less preoccupation with food while on therapy
In a complaint filed in federal court for the Northern District of Texas, the Outsourcing Facilities Association and North American Custom Laboratories claimed the FDA's decision was arbitrary, capricious, and contrary to law because the agency didnt notify compounders in advance, nor allow for public comment
By focusing on mitigating oxidative damage, controlling inflammatory cascades and modulating hepatocyte reprogramming, we can advance the treatment of ALD
